

**Supplementary Table 1.** Baseline clinicopathologic characteristics of the 62 patients with NSCLC treated with immunotherapy.

Characteristic	N = 62 (%)
Age, median (range)	61.5 (39-89)
Sex:	
Male	25 (40.3)
Female	37 (59.7)
Smoking status:	
Ever	53 (85.5)
Never	9 (14.5)
ECOG performance status:	
0-1	55 (88.7)
≥2	7 (11.3)
Histology:	
Non-squamous	56 (90.3)
Squamous	6 (9.7)
Mutation status by tissue next generation sequencing:	
<i>KRAS</i>	21 (35.0)
<i>EGFR</i>	4 (6.6)
<i>BRAF</i>	6 (10.0)
<i>MET exon 14</i>	2 (3.3)
<i>HER2</i>	2 (3.3)
<i>ALK</i>	1 (1.6)
<i>ROS1</i>	1 (1.6)
None identified	23 (38.3)
Not assessed	2
Treatment received:	
Carboplatin/Pemetrexed/Pembrolizumab	31 (50.0)
Pembrolizumab	31 (50.0)
PD-L1 tumor proportion score:	
<1%	13 (23.2)
1-49%	10 (17.8)
≥50%	33 (58.9)
Not assessed	6
TMB, median (range), mutations/megabase	9.8 (1.5-41.8)

ECOG, Eastern Cooperative Oncology Group  
 PD-L1, programmed death ligand 1  
 TMB, tumor mutational burden.